Immune Response Settles Shareholder Suits

Law360, New York (November 15, 2006, 12:00 AM EST) -- The Immune Response Corp. said Tuesday that it will pay nearly $10 million to settle a pair of securities class action lawsuits that accused it of misrepresenting the efficacy of its AIDS-treatment drug Remune.

In the federal case, which is still subject to court approval, Immune Response agreed to pay the affected shareholders $9.6 million. Meanwhile, in the related case before the California state courts, the pharmaceutical company agreed to pay $250,000 and adopt certain corporate governance requirements.

A settlement approval hearing on the state case...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.